Abstract 58P
Background
Myelodysplastic syndromes (MDS) are a group of blood cancers which are characterized by ineffective hematopoiesis of bone marrow cells and abnormal blood cell development leading to cytopenias and an increased risk for progression to acute myeloid leukemia. At diagnosis, 50% of MDS patients have a normal conventional karyotype, however, unbalanced chromosomal aberrations are common and have prognostic implications. We aimed to investigate the unbalanced chromosomal aberrations in MDS patients with normal bone marrow karyotype using micro-array-based Comparative Genomic Hybridization (aCGH).
Methods
aCGH was performed on peripheral blood extracted DNA from 5 patients with clinical MDS features and normal bone marrow karyotype and we employed a Multiplex Ligation-dependent Probe Amplification (MLPA®) analysis to confirm the Subtelomeric copy number variations (CNVs).
Results
The aCGH analysis (NCBI36/hg18) revealed copy-number variations (CNV) in all patients with normal karyotype. All the 5 patients carried 16 copy-number variations (CNV), including 8 duplications ranging from 20 killobases (Kb) to 2,283 megabases (Mb), they include chromosomal regions 1q44; 2p16; 5q12, 10q27;14q12; 22q11; Xq21.3; Xq27.3 and 8 deletions ranging from 26.3 Kb to 948.9 kb, including chromosomal regions 1p36.1; 1q21; 4q31; 5p15.4; 9q21.1; 10q24; 22q21. Subtelomeric CNV (5p15; 10q27 and 1q44) were approved by using Multiplex Ligation-dependent Probe Amplification (MLPA®) analysis with SALSA MLPA Probemix P036 Subtelomeres Mix 1.
Conclusions
These results demonstrated that chromosomal defects in MDS may be more frequent than predicted by metaphase cytogenetics and new cryptic lesions may be revealed by precise analysis methods. This study suggests a significant role for the use of aCGH in the clinical workup of MDS patients.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
136P - Molecular correlates of drug response to guide therapy in TNBC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
137P - Event-free survival prediction using lncRNAs in pediatric B-cell acute lymphoblastic leukemia
Presenter: Unai Illarregi
Session: Cocktail & Poster Display session
Resources:
Abstract
138P - Exome sequencing analysis for the identification of actionable mutations related to neoadjuvant chemotherapy response in locally advanced breast cancer
Presenter: Ximena López
Session: Cocktail & Poster Display session
Resources:
Abstract
139P - Genomic prognostic and potential theragnostic factors in anal squamous cell carcinoma treated with abdominoperineal resection
Presenter: Abderaouf Hamza
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Correlation of EZH2 expression and response to chemoradiotherapy in patients with locally advanced inoperable oral cavity and oropharyngeal squamous cell cancers
Presenter: Soel Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
140P - Predictive value of DNA damage response and repair gene alterations and neoscore for neoadjuvant immunotherapies in non-small cell lung cancer
Presenter: Fei Feng
Session: Cocktail & Poster Display session
Resources:
Abstract
141P - Immune-related epigenomic and transcriptomic signatures to predict immunotherapy response in NSCLC
Presenter: María Gallardo-Gómez
Session: Cocktail & Poster Display session
Resources:
Abstract
142P - Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - Genomic characterization and outcomes of patients with primary sclerosing cholangitis-related cholangiocarcinoma
Presenter: Jaime Haro Silerio
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract